BLCM Bellicum Pharmaceuticals, Inc.

13.86
+0  (2%)
Previous Close 13.61
Open 13.73
Price To book 3.83
Market Cap 376.40M
Shares 27,157,000
Volume 459,571
Short Ratio 6.29
Av. Daily Volume 621,268

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 planned 2H 2016
BPX-401
Hematological cancers that express the CD19 antigen
Phase 1/2 update February 22, 2017.
BPX-501 - BP-004
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 2 trial initiation of dosing announced February 21, 2017.
BPX-601
Pancreatic cancer
Phase 1/2 commenced March 2017.
BPX-701
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer

Latest News

  1. Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
  2. Biotech Movers: XBiotech, Atara, Bellicum
  3. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : April 11, 2017
  4. The First CAR-T Drugs Have Left the Gate
  5. Biotech Movers: Sarepta, Bellicum, Novavax
  6. Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
  7. Bellicum Pharmaceuticals Announces Closing of Public Offering
  8. Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma
  9. ETFs with exposure to Bellicum Pharmaceuticals, Inc. : March 27, 2017
  10. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : March 24, 2017
  11. Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  12. Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
  13. Bellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  14. 5 Stocks Trending Close to Major Breakouts
  15. Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  16. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : March 13, 2017
  17. Here's Why Bellicum Pharmaceuticals Went Up as Much as 22% Today
  18. Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference
  19. Better Buy: Bellicum Pharmaceuticals Inc. vs. bluebird bio Inc.
  20. Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017